Operating through 123 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared,non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 370,000 TMS treatments to close to 10,000 patients struggling with depression.
Company profile
Ticker
GBNH
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
GBNH stock data
Analyst ratings and price targets
Latest filings (excl ownership)
6-K
Current report (foreign)
23 May 23
6-K
Greenbrook TMS Receives Notifications Regarding Nasdaq Listing Deficiencies
19 May 23
6-K
GREENBROOK TMS REPORTS FIRST quarter operational and FINANCIAL RESULTS
15 May 23
6-K
Greenbrook TMS Inc. 6-K
10 May 23
20-F
2022 FY
Annual report (foreign)
17 Apr 23
6-K
GREENBROOK TMS REPORTS FISCAL 2022 operational and FINANCIAL RESULTS
17 Apr 23
6-K
Greenbrook TMS Announces Dates for Its Fourth Quarter and Year End 2022 Financial Results
14 Apr 23
6-K
Greenbrook TMS Inc. 6-K
14 Apr 23
6-K
Greenbrook TMS Provides Bi-weekly Mcto Status Update
12 Apr 23
6-K
Greenbrook TMS Announces Acceptance of Its Management Cease Trade Order Application
6 Apr 23
Latest ownership filings
SC 13D
Madryn Asset Management, LP
3 Apr 23
SC 13D/A
MSS GB SPV LP
29 Mar 23
SC 13D/A
Vamvakas Family Trust
24 Mar 23
SC 13D
Vamvakas Family Trust
10 Mar 23
SC 13D
Klein Benjamin
27 Jul 22
SC 13G
Madryn Asset Management, LP
25 Jul 22
SC 13G
Vamvakas Family Trust
17 Feb 22
SC 13G
Greybrook Health Inc.
14 Feb 22
SC 13D/A
MSS GB SPV LP
2 Dec 21
SC 13D
MSS GB SPV LP
24 Jun 21
Financial summary
| Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
Institutional ownership, Q4 2022
58.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 17 |
| Opened positions | 3 |
| Closed positions | 1 |
| Increased positions | 2 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 1.95 bn |
| Total shares | 17.29 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Greybrook Health | 4.73 mm | $0.00 |
| Vamvakas Family Trust | 4.73 mm | $19.95 mm |
| Klein Benjamin | 3.87 mm | $5.23 mm |
| 1315 Capital II | 2.07 mm | $23.86 mm |
| MSS GB SPV | 900.00 k | $4.76 mm |
| Masters Capital Management | 700.00 k | $1.35 bn |
| AdvisorShares Investments | 117.43 k | $234.86 mm |
| AWM Investment | 71.77 k | $144.71 mm |
| BMO Bank of Montreal | 32.56 k | $68.30 mm |
| UBS UBS Group AG - Registered Shares | 17.67 k | $34.10 mm |
News
Greenbrook TMS Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $19.91M Beat $18.92M Estimate
16 May 23
Earnings Scheduled For May 15, 2023
15 May 23
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
12 May 23
Preview: Greenbrook TMS's Earnings
12 May 23
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
19 Apr 23
Press releases
GREENBROOK TMS REPORTS FIRST QUARTER OPERATIONAL AND FINANCIAL RESULTS
15 May 23
Greenbrook TMS Announces Dates for Its First Quarter 2023 Financial Results
10 May 23
Greenbrook TMS Reports Fiscal 2022 Operational and Financial Results
17 Apr 23
Greenbrook TMS Announces Dates for Its Fourth Quarter and Year End 2022 Financial Results
14 Apr 23
GREENBROOK TMS PROVIDES BI-WEEKLY MCTO STATUS UPDATE
12 Apr 23